Iowa State University researchers discover structure of key Ebola proteinJanuary 13, 2009AMES, Iowa -- Research led by Iowa State University scientists has them a step closer to finding a way to counter the Ebola virus. A team led by Gaya Amarasinghe, an assistant professor in biochemistry, biophysics and molecular biology, has recently solved the structure from a key part of the Ebola protein known as VP35. VP35 interferes with the natural resistance of host cells against viral infections. "Usually when viruses infect cells, the host immune system can fight to eventually clear the virus. But with Ebola infections, the ability of the host to mount a defense against the invading virus is lost," said Amarasinghe. This is because the VP35 protein interferes with the host's innate immune pathways that form the first line of defense against pathogens, he said. In their research directed toward understanding host-viral interactions, Amarasinghe and his research team used a combination of X-ray crystallography and nucleic magnetic resonance spectroscopy to solve the structure using non-infectious protein samples. A report describing the findings is published this week in the journal Proceedings of the National Academy of Sciences of the United States of America. Now that the structure from a key part of VP35 is available, this information can be used as a template for anti-viral drug discovery. "The next step is to use this structure to identify and design drugs that potentially bind with VP35," he said. If a drug that inhibits VP35 function can be discovered, then the Ebola virus could potentially be neutralized. "Without functional VP35, the Ebola virus cannot replicate so it is noninfectious," said Amarasinghe. The Ebola virus can cause hemorrhagic fever that is usually fatal. According to the Center for Disease Control and Prevention, outbreaks have caused more than 1,000 deaths, mostly in Central Africa, since it was first recognized in 1976. Amarasinghe co-authored this study with Daisy Leung, assistant scientist; Nathaniel Ginder, graduate student; Bruce Fulton, associate scientist; and Richard Honzatko, professor; all from Iowa State's biochemistry, biophysics and molecular biology department, together with Christopher Basler, associate professor from Mount Sinai School of Medicine in New York City and Jay Nix from the Berkeley National Laboratory in Berkeley, Calif. Work in the Amarasinghe laboratory was funded in part by the Roy J. Carver Charitable Trust. Iowa State University of Science and Technology |
|||||||||||||||||||||
| Related Ebola Current Events and Ebola News Articles 1930s drug slows tumor growth Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease. Exon-skipping drug prevents muscle wasting, maintains muscle function in dystrophin deficient mice An exon skipping PPMO has demonstrated dramatic effects in the prevention and treatment of severely affected, dystrophin and utrophin-deficient mice, preventing severe deterioration of the treated animals and extending their lifespan. Outfoxing pox: Developing a new class of vaccine candidates In the annals of medicine, Edward Jenner's 1796 vaccination of a young boy against smallpox, using fluid from cowpox blisters, remains a landmark case. In a new study, Kathryn Sykes, a researcher at Arizona State University's Biodesign Institute and her colleagues have taken a fresh look at cowpox. World will miss 2010 target to stem biodiversity loss, experts say The world will miss its agreed target to stem biodiversity loss by next year, according to experts convening in Cape Town for a landmark conference devoted to biodiversity science. Scientists block Ebola infection in cell-culture experiments Researchers at the University of Texas Medical Branch at Galveston have discovered two biochemical pathways that the Ebola virus relies on to infect cells. OHSU scientists partner with others to form center aimed at combating infectious diseases Oregon Health & Science University and the University of Washington, along with a number of partner institutions across the Northwest, have received federal funding to form a regional research center aimed at combating emerging or re-emerging infectious diseases that pose a serious threat to human health. Drug blocks 2 of world's deadliest emerging viruses Two highly lethal viruses that have emerged in recent outbreaks are susceptible to chloroquine, an established drug used to prevent and treat malaria, according to a new basic science study by researchers at Weill Cornell Medical College in the Journal of Virology. Penn Study Identifies How Ebola Virus Avoids the Immune System Researchers at the University of Pennsylvania School of Medicine have likely found one reason why the Ebola virus is such a powerful, deadly, and effective virus. Using a cell culture model for Ebola virus infection, they have discovered that the virus disables a cellular protein called tetherin that normally can block the spread of virus from cell to cell. UT Southwestern researchers develop new strategy for broad spectrum anti-viral drugs Bavituximab, an anti-viral drug developed by UT Southwestern Medical Center researchers, shows promise as a new strategy to fight viral diseases, including potential bioterrorism agents. Scientists discover new species of Ebola virus Scientists report the discovery of a new species of Ebola virus, provisionally named Bundibugyo ebolavirus, November 21 in the open-access journal PLoS Pathogens. More Ebola Current Events and Ebola News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||